Skip to content
  • Rheuma Pics Hub
  • Rheuma Calculator
  • Books
  • Account
  • Dashboard
  • Login
  • Logout
  • Register
  • Rheuma Tv in 2024
Rheuma Tv
  • Home
  • Student Corner
    • PG Section
    • UG Section
  • Case Discussion
  • Research
    • Journal Club
  • Webinar
    • Live Webinar
      • Biologics in AIRD
      • AIRD and INFLAMMATION
      • SLE and Inflammation
      • Immunology and Inflammation
      • Eye and Rheumatology Series
      • Investigation in Rheumatology
      • Expert Talk
      • Tofacitinib in Rheumatology
      • CS DMARDS in RA
    • Past Webinar
    • Webinar Registration
  • News and Views
  • Conference
    • ChanRe Update 2024
    • ChanRe Update 2023
    • ChanRe Update 2022
    • ChanRe Update 2021
    • SIRCON 2023
    • Karnataka Vasculitis Club
  • Quiz
  • Courses

Disease modifying anti-rheumatic drugs

Increased expression of CC chemokine receptor 4 may predict the efficacy of RA treatment

August 11, 2023

The CC chemokine receptor 4 (CCR4) serves as a receptor for two chemokines: thymus and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC). It has been …

Read more

The use of DMARDs may be associated with different levels of diabetes risk in RA patients

July 25, 2023

Patients with rheumatoid arthritis (RA) are more prone to diabetes than the general population, leading to an elevated risk of cardiovascular disease. A study featured …

Read more

Tofacitinib is non-inferior to adalimumab in the treatment of rheumatoid arthritis

July 12, 2023

In a randomized controlled trial published in JAMA Network Open, it was found that the effectiveness of tofacitinib is comparable to adalimumab for treating rheumatoid …

Read more

Peresolimab, a humanized IgG1 monoclonal antibody treatment for rheumatoid arthritis, shows promising results in phase 2a trial

July 8, 2023July 8, 2023

According to a phase 2a study published in New England Journal of Medicine, peresolimab has shown effectiveness in rheumatoid arthritis (RA) patients. Peresolimab is a …

Read more

Important Links

  • Privacy Policy
  • Contact Us
  • Disclaimer
  • About Us
  • Terms and Conditions
  • Cancellation Policy
  • Refund Policy
  • Partner With Us

Disclaimer

This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. @2020 ChanRe Healthcare & Research Pvt Ltd.

Copyright © 2025 DMCA.com Protection Status
  • Home
  • Student Corner
    • PG Section
    • UG Section
  • Case Discussion
  • Research
    • Journal Club
  • Webinar
    • Live Webinar
      • Biologics in AIRD
      • AIRD and INFLAMMATION
      • SLE and Inflammation
      • Immunology and Inflammation
      • Eye and Rheumatology Series
      • Investigation in Rheumatology
      • Expert Talk
      • Tofacitinib in Rheumatology
      • CS DMARDS in RA
    • Past Webinar
    • Webinar Registration
  • News and Views
  • Conference
    • ChanRe Update 2024
    • ChanRe Update 2023
    • ChanRe Update 2022
    • ChanRe Update 2021
    • SIRCON 2023
    • Karnataka Vasculitis Club
  • Quiz
  • Courses